13

Mobocertinib

13 Publications Verification

Cat. No.: HY-135815

CAS No.: 1847461-43-1

Purity: 99.60%

Synonyms: TAK-788; AP32788

Target:

EGFR

Research Areas:

Cancer

Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

13

Mobocertinib succinate

13 Publications Verification

Cat. No.: HY-135815A

CAS No.: 2389149-74-8

Purity: 99.83%

Synonyms: TAK-788 succinate; AP32788 succinate

Target:

EGFR

Research Areas:

Cancer

Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

11

Almonertinib

11 Cited Publications

Cat. No.: HY-112823

CAS No.: 1899921-05-1

Purity: 99.83%

Synonyms: HS-10296

Target:

EGFR

Research Areas:

Cancer

Almonertinib (HS-10296) is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib is used for the research of the non-small cell lung cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

11

Almonertinib mesylate

11 Cited Publications

Cat. No.: HY-112823A

CAS No.: 2134096-06-1

Purity: 99.67%

Synonyms: HS-10296 mesylate

Target:

EGFR

Research Areas:

Cancer

Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

11

Almonertinib hydrochloride

11 Cited Publications

Cat. No.: HY-112823B

CAS No.: 2134096-03-8

Purity: 99.77%

Synonyms: HS-10296 hydrochloride

Target:

EGFR

Research Areas:

Cancer

Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib hydrochloride shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib hydrochloride is used for the research of the non-small cell lung cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

6

Firmonertinib

6 Cited Publications

Cat. No.: HY-112870

CAS No.: 1869057-83-9

Purity: 99.89%

Synonyms: Alflutinib; Furmonertinib; AST2818

Target:

EGFR

Research Areas:

Cancer

Firmonertinib (Alflutinib; Furmonertinib) is an orally active, mutant-selective, and highly brain penetrant EGFR inhibitor. Firmonertinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

6

Firmonertinib mesylate

6 Cited Publications

Cat. No.: HY-112870A

CAS No.: 2130958-55-1

Purity: 99.97%

Synonyms: Alflutinib mesylate; Furmonertinib mesylate; AST2818 mesylate

Target:

EGFR

Research Areas:

Inflammation/Immunology Cancer

Firmonertinib (Alflutinib; Furmonertinib) mesylate is is an orally active, mutant-selective, and blood-brain barrier penetrant EGFR inhibitor. Firmonertinib mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib mesylate has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

Sunvozertinib

4 Cited Publications

Cat. No.: HY-132842

CAS No.: 2370013-12-8

Purity: 99.71%

Synonyms: DZD9008

Target:

EGFR Btk

Research Areas:

Cancer

Sunvozertinib (DZD9008) is a potent ErbBs (EGFR, Her2, especially mutant forms) and BTK inhibitor. Sunvozertinib shows IC₅₀s of 20.4, 20.4, 1.1, 7.5, and 80.4 nM for EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, and Her2 Exon20 YVMA, and EGFR WT A431, respectively (patent WO2019149164A1, example 52) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

Gefitinib-based PROTAC 3

4 Cited Publications

Cat. No.: HY-123921

CAS No.: 2230821-27-7

Purity: 99.98%

Target:

PROTACs EGFR

Research Areas:

Cancer

Gefitinib-based PROTAC 3 is a PROTAC degrader targeting EGFR, with a DC₅₀ of 11.7 nM against exon 19 deletion mutants and a DC₅₀ of 22.3 nM against EGFR ^L858R. Gefitinib-based PROTAC 3 selectively induces the ubiquitin-proteasome degradation of exon 19 deletion-mutant and L858R-mutant EGFR by recruiting the VHL E3 ligase. Gefitinib-based PROTAC 3 can be used for the research of EGFR mutation-positive cancers .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

3

Zipalertinib

3 Cited Publications

Cat. No.: HY-112299

CAS No.: 1661854-97-2

Purity: 99.81%

Synonyms: TAS6417; CLN-081

Target:

EGFR Apoptosis

Research Areas:

Cancer

Zipalertinib (TAS6417; CLN-081) is a highly effective, orally active and pan-mutation-selective EGFR tyrosine kinase inhibitor with a unique scaffold fitting into the ATP-binding site of the EGFR hinge region, with IC₅₀ values ranging from 1.1-8.0 nM .

Compare

loading...